Results 11 to 20 of about 46,179 (165)

Patterns of CMR measured longitudinal strain and its association with late gadolinium enhancement in patients with cardiac amyloidosis and its mimics

Journal of Cardiovascular Magnetic Resonance, 2017
Background Regional variability of longitudinal strain (LS) has been previously described with echocardiography in patients with cardiac amyloidosis (CA), however, the reason for this variability is not completely evident.
Lynne K. Williams, Julian F. Forero, Zoran B. Popovic, Dermot Phelan, Diego Delgado, Harry Rakowski, Bernd J. Wintersperger, Paaladinesh Thavendiranathan   +7 more
doaj   +1 more source

Cardiotoxicity

Annals of Oncology, 2010
Cancer treatment has improved extraordinarily in recent years. The development of targeted therapies has widened the cardiotoxic spectrum of antineoplastic drugs. Optimum management of cardiovascular disease before and during antineoplastic treatment is essential to reduce morbidity and mortality in cancer patients.
I, Brana, J, Tabernero
openaire   +2 more sources

Bibliometric and visual analysis of doxorubicin-induced cardiotoxicity

Frontiers in Pharmacology, 2023
Background: Doxorubicin-induced cardiotoxicity represents a prevalent adverse effect encountered in patients undergoing treatment with doxorubicin. To date, there has been no bibliometric study to summarize the field of doxorubicin-induced cardiotoxicity.
Xiaoxiao Lin, Guomin Wu, Shuai Wang, Jinyu Huang   +3 more
doaj   +1 more source

Human Pluripotent Stem Cells for Modeling of Anticancer Therapy-Induced Cardiotoxicity and Cardioprotective Drug Discovery

Frontiers in Pharmacology, 2021
Anticancer chemotherapies have been shown to produce severe side effects, with cardiotoxicity from anthracycline being the most notable. Identifying risk factors for anticancer therapy-induced cardiotoxicity in cancer patients as well as understanding ...
Wendy Keung, Yiu-Fai Cheung, Yiu-Fai Cheung   +2 more
doaj   +1 more source

Nrf2: a dark horse in doxorubicin-induced cardiotoxicity

Cell Death Discovery, 2023
Being a broad-spectrum anticancer drug, doxorubicin is indispensable for clinical treatment. Unexpectedly, its cardiotoxic side effects have proven to be a formidable obstacle.
Xiaopeng Zhao, Zheng Tian, Mingli Sun, Dan Dong   +3 more
doaj   +1 more source

Early detection of anthracycline‐ and trastuzumab‐induced cardiotoxicity: value and optimal timing of serum biomarkers and echocardiographic parameters

ESC Heart Failure, 2022
Aims To evaluate echocardiographic and biomarker changes during chemotherapy, assess their ability to early detect and predict cardiotoxicity and to define the best time for their evaluation. Methods and results Seventy‐two women with breast cancer (52 ± 
Belén Díaz‐Antón, Rodrigo Madurga, Blanca Zorita, Samantha Wasniewski, Andrea Moreno‐Arciniegas, Beatriz López‐Melgar, Natalia Ramírez Merino, Roberto Martín‐Asenjo, Patricia Barrio, Maximiliano German Amado Escañuela, Jorge Solís, Francisco Javier Parra Jiménez, Eva Ciruelos, José María Castellano, Leticia Fernández‐Friera   +14 more
doaj   +1 more source

Prognostic Factors for Cardiotoxicity among Children with Cancer: Definition, Causes, and Diagnosis with Omics Technologies

Diagnostics, 2023
Improvements in the treatment of childhood cancer have considerably enhanced survival rates over the last decades to over 80% as of today. However, this great achievement has been accompanied by the occurrence of several early and long-term treatment ...
Kondylia Antoniadi, Nikolaos Thomaidis, Petros Nihoyannopoulos, Konstantinos Toutouzas, Evangelos Gikas, Charikleia Kelaidi, Sophia Polychronopoulou   +6 more
doaj   +1 more source

Imaging of Cardiotoxicity

Molecular Imaging, 2008
A driamycin (ADR; doxorubicin HCl), is a potent anthracycline chemotherapeutic agent that is effective against a wide range of human malignancies, such as leukemias, lymphomas, and many solid tumors. For many malignancies (eg, breast cancer, lymphoma), it is the most effective single agent.
Jerry D. Glickson, John R. Forder, John C. Chatham   +2 more
openaire   +3 more sources

Cardiotoxicity of immune checkpoint inhibitors: A frequency network meta-analysis

Frontiers in Immunology, 2022
Immune checkpoint inhibitors (ICIs) in combination withother anti-cancer treatments have been approved for a variety of cancers. While the difference in the incidence of cardiovascular adverse events has not been fully investigated.
Maobai Liu, Maobai Liu, Xitong Cheng, Xitong Cheng, Ruping Ni, Ruping Ni, Bin Zheng, Bin Zheng, Shunmin Huang, Shunmin Huang, Jing Yang, Jing Yang   +11 more
doaj   +1 more source

Prevalence and Risk Factors of Cardiotoxicity in Elderly Cancer Patients [PDF]

The Egyptian Journal of Geriatrics and Gerontology, 2023
Background: Cancer and heart disease are the leading causes of death in older adults. Cardiotoxicity of anticancer agents may lead to under-treatment of elderly patients, resulting in suboptimal outcomes.Aim: To determine the prevalence and risk factors ...
Maha A.Ali, Hala Samir Sweed, Mohamed Ahmed Alsadany, Ghada Kazamel, Mohamed F.Tolba   +4 more
doaj   +1 more source